{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T12:34:34Z","timestamp":1788957274282,"version":"build-2803163510"},"reference-count":88,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2021,7,13]],"date-time":"2021-07-13T00:00:00Z","timestamp":1626134400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,7,13]],"date-time":"2021-07-13T00:00:00Z","timestamp":1626134400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"NSRF","award":["INSPIRED \/ MIS5002550"],"award-info":[{"award-number":["INSPIRED \/ MIS5002550"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetologia"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1007\/s00125-021-05509-0","type":"journal-article","created":{"date-parts":[[2021,7,13]],"date-time":"2021-07-13T13:03:21Z","timestamp":1626181401000},"page":"1917-1926","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":79,"title":["HDL and type 2 diabetes: the chicken or the egg?"],"prefix":"10.1007","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0903-2637","authenticated-orcid":false,"given":"Eva","family":"Xepapadaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8949-2026","authenticated-orcid":false,"given":"Ioanna","family":"Nikdima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8146-826X","authenticated-orcid":false,"given":"Eleftheria C.","family":"Sagiadinou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8387-6830","authenticated-orcid":false,"given":"Evangelia","family":"Zvintzou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6784-2710","authenticated-orcid":false,"given":"Kyriakos E.","family":"Kypreos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,13]]},"reference":[{"issue":"1","key":"5509_CR1","doi-asserted-by":"publisher","first-page":"E1","DOI":"10.1152\/ajpendo.00429.2015","volume":"310","author":"C Constantinou","year":"2016","unstructured":"Constantinou C, Karavia EA, Xepapadaki E et al (2016) Advances in high-density lipoprotein physiology: surprises, overturns, and promises. Am J Physiol Endocrinol Metab 310(1):E1\u2013E14. https:\/\/doi.org\/10.1152\/ajpendo.00429.2015","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"4","key":"5509_CR2","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1586\/14779072.2014.896741","volume":"12","author":"EA Karavia","year":"2014","unstructured":"Karavia EA, Zvintzou E, Petropoulou PI, Xepapadaki E, Constantinou C, Kypreos KE (2014) HDL quality and functionality: What can proteins and genes predict? Expert Rev Cardiovasc Ther 12(4):521\u2013532. https:\/\/doi.org\/10.1586\/14779072.2014.896741","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"5509_CR3","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1177\/0003319719854609","volume":"71","author":"E Xepapadaki","year":"2020","unstructured":"Xepapadaki E, Zvintzou E, Kalogeropoulou C, Filou S, Kypreos KE (2020) \u03a4he Antioxidant Function of HDL in Atherosclerosis. Angiology 71:112\u2013121. https:\/\/doi.org\/10.1177\/0003319719854609","journal-title":"Angiology"},{"issue":"1","key":"5509_CR4","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.atherosclerosis.2009.05.034","volume":"208","author":"EM Tsompanidi","year":"2010","unstructured":"Tsompanidi EM, Brinkmeier MS, Fotiadou EH, Giakoumi SM, Kypreos KE (2010) HDL biogenesis and functions: Role of HDL quality and quantity in atherosclerosis. Atherosclerosis 208(1):3\u20139. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2009.05.034","journal-title":"Atherosclerosis"},{"issue":"3","key":"5509_CR5","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1152\/physrev.1954.34.3.589","volume":"34","author":"JW Gofman","year":"1954","unstructured":"Gofman JW, Glazier F, Tamplin A, Strisower B, De LO (1954) Lipoproteins, coronary heart disease, and atherosclerosis. Physiol Rev 34(3):589\u2013607. https:\/\/doi.org\/10.1152\/physrev.1954.34.3.589","journal-title":"Physiol Rev"},{"issue":"7897","key":"5509_CR6","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/s0140-6736(75)92376-4","volume":"1","author":"GJ Miller","year":"1975","unstructured":"Miller GJ, Miller NE (1975) Plasma-high-density-lipoprotein concentration and development of ischaemic heart-disease. Lancet 1(7897):16\u201319. https:\/\/doi.org\/10.1016\/s0140-6736(75)92376-4","journal-title":"Lancet"},{"issue":"1","key":"5509_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0021-9150(01)00651-7","volume":"161","author":"JR Nofer","year":"2002","unstructured":"Nofer JR, Kehrel B, Fobker M, Levkau B, Assmann G, von Eckardstein A (2002) HDL and arteriosclerosis: Beyond reverse cholesterol transport. Atherosclerosis 161(1):1\u201316. https:\/\/doi.org\/10.1016\/S0021-9150(01)00651-7","journal-title":"Atherosclerosis"},{"key":"5509_CR8","doi-asserted-by":"publisher","first-page":"985","DOI":"10.5551\/jat.RV17025","volume":"25","author":"M Nagao","year":"2018","unstructured":"Nagao M, Nakajima H, Toh R, Hirata KI, Ishida T (2018) Cardioprotective effects of high-density lipoprotein beyond its anti-atherogenic action. J Atheroscler Thromb 25:985\u2013993. https:\/\/doi.org\/10.5551\/jat.RV17025","journal-title":"J Atheroscler Thromb"},{"issue":"4","key":"5509_CR9","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.jacl.2014.05.001","volume":"8","author":"E Zvintzou","year":"2014","unstructured":"Zvintzou E, Skroubis G, Chroni A et al (2014) Effects of bariatric surgery on HDL structure and functionality: Results from a prospective trial. J Clin Lipidol 8(4):408\u2013417. https:\/\/doi.org\/10.1016\/j.jacl.2014.05.001","journal-title":"J Clin Lipidol"},{"issue":"1","key":"5509_CR10","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.atherosclerosis.2011.10.017","volume":"220","author":"AE Kavo","year":"2012","unstructured":"Kavo AE, Rallidis LS, Sakellaropoulos GC et al (2012) Qualitative characteristics of HDL in young patients of an acute myocardial infarction. Atheroscler 220(1):257\u2013264. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2011.10.017","journal-title":"Atheroscler"},{"issue":"27","key":"5509_CR11","doi-asserted-by":"publisher","first-page":"3752","DOI":"10.1021\/acs.biochem.6b00389","volume":"55","author":"S Filou","year":"2016","unstructured":"Filou S, Lhomme M, Karavia EA et al (2016) Distinct Roles of Apolipoproteins A1 and e in the Modulation of High-Density Lipoprotein Composition and Function. Biochemistry 55(27):3752\u20133762. https:\/\/doi.org\/10.1021\/acs.biochem.6b00389","journal-title":"Biochemistry"},{"issue":"9","key":"5509_CR12","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1194\/jlr.M077925","volume":"58","author":"E Zvintzou","year":"2017","unstructured":"Zvintzou E, Lhomme M, Chasapi S et al (2017) Pleiotropic effects of apolipoprotein C3 on HDL functionality and adipose tissue metabolic activity. J Lipid Res 58(9):1869\u20131883. https:\/\/doi.org\/10.1194\/jlr.M077925","journal-title":"J Lipid Res"},{"issue":"1","key":"5509_CR13","doi-asserted-by":"publisher","first-page":"14","DOI":"10.7555\/JBR.33.20190048","volume":"34","author":"E Zvintzou","year":"2020","unstructured":"Zvintzou E, Xepapadaki E, Kalogeropoulou C, Filou S, Kypreos KE (2020) Pleiotropic effects of apolipoprotein A-II on high-density lipoprotein functionality, adipose tissue metabolic activity and plasma glucose homeostasis. J Biomed Res 34(1):14\u201326. https:\/\/doi.org\/10.7555\/JBR.33.20190048","journal-title":"J Biomed Res"},{"issue":"9841","key":"5509_CR14","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/S0140-6736(12)60312-2","volume":"380","author":"BF Voight","year":"2012","unstructured":"Voight BF, Peloso GM, Orho-Melander M et al (2012) Plasma HDL cholesterol and risk of myocardial infarction: A mendelian randomisation study. Lancet 380(9841):572\u2013580. https:\/\/doi.org\/10.1016\/S0140-6736(12)60312-2","journal-title":"Lancet"},{"issue":"2","key":"5509_CR15","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1210\/jc.2011-1846","volume":"97","author":"CL Haase","year":"2012","unstructured":"Haase CL, Tybj\u00e6rg-Hansen A, Ali Qayyum A, Schou J, Nordestgaard BG, Frikke-Schmidt R (2012) LCAT, HDL cholesterol and ischemic cardiovascular disease: A mendelian randomization study of HDL cholesterol in 54,500 individuals. J Clin Endocrinol Metab 97(2):248\u2013256. https:\/\/doi.org\/10.1210\/jc.2011-1846","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"5509_CR16","doi-asserted-by":"publisher","first-page":"2676","DOI":"10.2337\/db14-1710","volume":"64","author":"T Fall","year":"2015","unstructured":"Fall T, Xie W, Poon W et al (2015) Using genetic variants to assess the relationship between circulating lipids and type 2 diabetes. Diabetes 64(7):2676\u20132684. https:\/\/doi.org\/10.2337\/db14-1710","journal-title":"Diabetes"},{"issue":"9965","key":"5509_CR17","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/S0140-6736(14)61183-1","volume":"385","author":"DI Swerdlow","year":"2015","unstructured":"Swerdlow DI, Preiss D, Kuchenbaecker KB et al (2015) HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: Evidence from genetic analysis and randomised trials. Lancet 385(9965):351\u2013361. https:\/\/doi.org\/10.1016\/S0140-6736(14)61183-1","journal-title":"Lancet"},{"key":"5509_CR18","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.2337\/db15-0458","volume":"64","author":"DI Swerdlow","year":"2015","unstructured":"Swerdlow DI, Sattar N (2015) Blood lipids and type 2 diabetes risk: Can genetics help untangle the web? Diabetes 64:2344\u20132345. https:\/\/doi.org\/10.2337\/db15-0458","journal-title":"Diabetes"},{"key":"5509_CR19","doi-asserted-by":"publisher","first-page":"100044","DOI":"10.1194\/JLR.P120001000","volume":"62","author":"DG Thomas","year":"2021","unstructured":"Thomas DG, Wei Y, Tall AR (2021) Lipid and metabolic syndrome traits in coronary artery disease: A Mendelian randomization study. J Lipid Res 62:100044. https:\/\/doi.org\/10.1194\/JLR.P120001000","journal-title":"J Lipid Res"},{"issue":"10","key":"5509_CR20","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.2215\/CJN.00730116","volume":"11","author":"B Bowe","year":"2016","unstructured":"Bowe B, Xie Y, Xian H, Balasubramanian S, Zayed MA, Al-Aly Z (2016) High density lipoprotein cholesterol and the risk of all-cause mortality among U.S. veterans. Clin J Am Soc Nephrol 11(10):1784\u20131793. https:\/\/doi.org\/10.2215\/CJN.00730116","journal-title":"Clin J Am Soc Nephrol"},{"issue":"19","key":"5509_CR21","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1016\/j.jacc.2016.08.038","volume":"68","author":"DT Ko","year":"2016","unstructured":"Ko DT, Alter DA, Guo H et al (2016) High-Density Lipoprotein Cholesterol and Cause-Specific Mortality in Individuals Without Previous Cardiovascular Conditions: The CANHEART Study. J Am Coll Cardiol 68(19):2073\u20132083. https:\/\/doi.org\/10.1016\/j.jacc.2016.08.038","journal-title":"J Am Coll Cardiol"},{"issue":"32","key":"5509_CR22","doi-asserted-by":"publisher","first-page":"2478","DOI":"10.1093\/eurheartj\/ehx163","volume":"38","author":"CM Madsen","year":"2017","unstructured":"Madsen CM, Varbo A, Nordestgaard BG (2017) Extreme high high-density lipoprotein cholesterol is paradoxically associated with high mortality inmen and women: Two prospective cohort studies. Eur Heart J 38(32):2478\u20132486. https:\/\/doi.org\/10.1093\/eurheartj\/ehx163","journal-title":"Eur Heart J"},{"issue":"4","key":"5509_CR23","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/0002-9149(83)90649-5","volume":"52","author":"WB Kannel","year":"1983","unstructured":"Kannel WB (1983) High-density lipoproteins: Epidemiologic profile and risks of coronary artery disease. Am J Cardiol 52(4):9\u201312. https:\/\/doi.org\/10.1016\/0002-9149(83)90649-5","journal-title":"Am J Cardiol"},{"issue":"3","key":"5509_CR24","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1177\/0003319718779533","volume":"70","author":"KE Kypreos","year":"2019","unstructured":"Kypreos KE, Bitzur R, Karavia EA, Xepapadaki E, Panayiotakopoulos G, Constantinou C (2019) Pharmacological Management of Dyslipidemia in Atherosclerosis: Limitations, Challenges, and New Therapeutic Opportunities. Angiology 70(3):197\u2013209. https:\/\/doi.org\/10.1177\/0003319718779533","journal-title":"Angiology"},{"issue":"1","key":"5509_CR25","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.jvs.2017.11.029","volume":"67","author":"L Bowman","year":"2018","unstructured":"Bowman L, Hopewell JC, Chen F et al (2018) Effects of Anacetrapib in Patients With Atherosclerotic Vascular Disease. J Vasc Surg 67(1):356. https:\/\/doi.org\/10.1016\/j.jvs.2017.11.029","journal-title":"J Vasc Surg"},{"key":"5509_CR26","doi-asserted-by":"publisher","first-page":"2156","DOI":"10.12659\/MSM.893619","volume":"21","author":"M Zeman","year":"2015","unstructured":"Zeman M, Vecka M, Perl\u00edk F et al (2015) Niacin in the treatment of hyperlipidemias in light of new clinical trials: Has niacin lost its place? Med Sci Monit 21:2156\u20132162. https:\/\/doi.org\/10.12659\/MSM.893619","journal-title":"Med Sci Monit"},{"issue":"24","key":"5509_CR27","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1056\/nejmoa1107579","volume":"365","author":"WE Boden","year":"2011","unstructured":"Boden WE, Probstfield JL, Anderson T et al (2011) Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy. N Engl J Med 365(24):2255\u20132267. https:\/\/doi.org\/10.1056\/nejmoa1107579","journal-title":"N Engl J Med"},{"issue":"3","key":"5509_CR28","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1056\/nejmoa1300955","volume":"371","author":"MJ Landray","year":"2014","unstructured":"Landray MJ, Haynes R, Hopewell JC et al (2014) Effects of Extended-Release Niacin with Laropiprant in High-Risk Patients. N Engl J Med 371(3):203\u2013212. https:\/\/doi.org\/10.1056\/nejmoa1300955","journal-title":"N Engl J Med"},{"issue":"1","key":"5509_CR29","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.atherosclerosis.2013.10.018","volume":"232","author":"C Tardy","year":"2014","unstructured":"Tardy C, Goffinet M, Boubekeur N et al (2014) CER-001, a HDL-mimetic, stimulates the reverse lipid transport and atherosclerosis regression in high cholesterol diet-fed LDL-receptor deficient mice. Atherosclerosis 232(1):110\u2013118. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2013.10.018","journal-title":"Atherosclerosis"},{"issue":"9","key":"5509_CR30","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1001\/jamacardio.2018.2121","volume":"3","author":"SJ Nicholls","year":"2018","unstructured":"Nicholls SJ, Andrews J, Kastelein JJP et al (2018) Effect of serial infusions of CER-001, a pre-\u03b2 High-density lipoprotein mimetic, on coronary atherosclerosis in patients following acute coronary syndromes in the CER-001 atherosclerosis regression acute coronary syndrome trial: A randomized clinical tria. JAMA Cardiol 3(9):815\u2013822. https:\/\/doi.org\/10.1001\/jamacardio.2018.2121","journal-title":"JAMA Cardiol"},{"issue":"10","key":"5509_CR31","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1161\/CIRCRESAHA.108.182063","volume":"103","author":"JA Shaw","year":"2008","unstructured":"Shaw JA, Bobik A, Murphy A et al (2008) Infusion of reconstituted high-density lipoprotein leads to acute changes in human atherosclerotic plaque. Circ Res 103(10):1084\u20131091. https:\/\/doi.org\/10.1161\/CIRCRESAHA.108.182063","journal-title":"Circ Res"},{"issue":"15","key":"5509_CR32","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1001\/jama.297.15.jpc70004","volume":"297","author":"JC Tardif","year":"2007","unstructured":"Tardif JC, Gr\u00e9goire J, L\u2019Allier PL et al (2007) Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: A randomized controlled trial. J Am Med Assoc 297(15):1675\u20131682. https:\/\/doi.org\/10.1001\/jama.297.15.jpc70004","journal-title":"J Am Med Assoc"},{"issue":"24","key":"5509_CR33","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1161\/CIRCULATIONAHA.116.025687","volume":"134","author":"CM Gibson","year":"2016","unstructured":"Gibson CM, Korjian S, Tricoci P et al (2016) Safety and Tolerability of CSL112, a Reconstituted, Infusible, Plasma-Derived Apolipoprotein A-I, after Acute Myocardial Infarction: The AEGIS-I Trial (ApoA-I Event Reducing in Ischemic Syndromes I). Circulation 134(24):1918\u20131930. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.116.025687","journal-title":"Circulation"},{"issue":"9","key":"5509_CR34","doi-asserted-by":"publisher","first-page":"2202","DOI":"10.1161\/ATVBAHA.113.301981","volume":"33","author":"S Diditchenko","year":"2013","unstructured":"Diditchenko S, Gille A, Pragst I et al (2013) Novel formulation of a reconstituted high-density lipoprotein (CSL112) dramatically enhances ABCA1-dependent cholesterol efflux. Arterioscler Thromb Vasc Biol 33(9):2202\u20132211. https:\/\/doi.org\/10.1161\/ATVBAHA.113.301981","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"5509_CR35","unstructured":"ClinicalTrials.gov (2018) Identifier NCT03473223, Study to investigate CSL112 in subjects with acute coronary syndrome (AEGIS-II). Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03473223. Accessed 8 June 2021"},{"issue":"2","key":"5509_CR36","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1161\/CIRCRESAHA.110.216507","volume":"107","author":"W D\u2019Souza","year":"2010","unstructured":"D\u2019Souza W, Stonik JA, Murphy A et al (2010) Structure\/function relationships of apolipoprotein A-I mimetic peptides: Implications for antiatherogenic activities of high-density lipoprotein. Circ Res 107(2):217\u2013227. https:\/\/doi.org\/10.1161\/CIRCRESAHA.110.216507","journal-title":"Circ Res"},{"issue":"11","key":"5509_CR37","doi-asserted-by":"publisher","first-page":"2302","DOI":"10.1194\/jlr.M800075-JLR200","volume":"49","author":"BJ Van Lenten","year":"2008","unstructured":"Van Lenten BJ, Wagner AC, Jung CL et al (2008) Anti-inflammatory apoA-I-mimetic peptides bind oxidized lipids with much higher affinity than human apoA-I. J Lipid Res 49(11):2302\u20132311. https:\/\/doi.org\/10.1194\/jlr.M800075-JLR200","journal-title":"J Lipid Res"},{"issue":"17","key":"5509_CR38","first-page":"232","volume":"108","author":"M Navab","year":"2003","unstructured":"Navab M, Hama S, Hough G, Reddy S, Anantharamaiah M, Fogelman A (2003) Oral administration of the apoA-I mimetic peptide D-4F causes the rapid formation and clearance of small anti-inflammatory HDL-like particles in mice. Circ 108(17):232","journal-title":"Circ"},{"issue":"25","key":"5509_CR39","doi-asserted-by":"publisher","first-page":"3215","DOI":"10.1161\/01.CIR.0000134275.90823.87","volume":"109","author":"M Navab","year":"2004","unstructured":"Navab M, Anantharamaiah GM, Reddy ST et al (2004) Oral D-4F causes formation of pre-beta high-density lipoprotein and improves high-density lipoprotein-mediated cholesterol efflux and reverse cholesterol transport from macrophages in apolipoprotein E-null mice. Circulation 109(25):3215\u20133220. https:\/\/doi.org\/10.1161\/01.CIR.0000134275.90823.87","journal-title":"Circulation"},{"issue":"6","key":"5509_CR40","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1111\/cts.12487","volume":"10","author":"RL Dunbar","year":"2017","unstructured":"Dunbar RL, Movva R, Bloedon LAT et al (2017) Oral Apolipoprotein A-I Mimetic D-4F Lowers HDL-Inflammatory Index in High-Risk Patients: A First-in-Human Multiple-Dose, Randomized Controlled Trial. Clin Transl Sci 10(6):455\u2013469. https:\/\/doi.org\/10.1111\/cts.12487","journal-title":"Clin Transl Sci"},{"key":"5509_CR41","doi-asserted-by":"publisher","first-page":"107843","DOI":"10.1016\/j.diabres.2019.107843","volume":"157","author":"P Saeedi","year":"2019","unstructured":"Saeedi P, Petersohn I, Salpea P et al (2019) Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract 157:107843. https:\/\/doi.org\/10.1016\/j.diabres.2019.107843","journal-title":"Diabetes Res Clin Pract"},{"issue":"6","key":"5509_CR42","doi-asserted-by":"publisher","first-page":"886","DOI":"10.2174\/1570161115666170201105425","volume":"15","author":"T Filippatos","year":"2017","unstructured":"Filippatos T, Tsimihodimos V, Pappa E, Elisaf M (2017) Pathophysiology of Diabetic Dyslipidaemia. Curr Vasc Pharmacol 15(6):886\u2013899. https:\/\/doi.org\/10.2174\/1570161115666170201105425","journal-title":"Curr Vasc Pharmacol"},{"issue":"5","key":"5509_CR43","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.2337\/db09-1114","volume":"59","author":"S Mora","year":"2010","unstructured":"Mora S, Otvos JD, Rosenson RS, Pradhan A, Buring JE, Ridker PM (2010) Lipoprotein particle size and concentration by nuclear magnetic resonance and incident type 2 diabetes in women. Diabetes 59(5):1153\u20131160. https:\/\/doi.org\/10.2337\/db09-1114","journal-title":"Diabetes"},{"key":"5509_CR44","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.diabres.2017.03.018","volume":"127","author":"Y Tabara","year":"2017","unstructured":"Tabara Y, Arai H, Hirao Y et al (2017) Different inverse association of large high-density lipoprotein subclasses with exacerbation of insulin resistance and incidence of type 2 diabetes: The Nagahama study. Diabetes Res Clin Pract 127:123\u2013131. https:\/\/doi.org\/10.1016\/j.diabres.2017.03.018","journal-title":"Diabetes Res Clin Pract"},{"issue":"12","key":"5509_CR45","first-page":"9437","volume":"276","author":"SH Koo","year":"2001","unstructured":"Koo SH, Dutcher AK, Towle HC (2001) Glucose and insulin function through two distinct transcription factors to stimulate expression of lipogenic enzyme genes in liver. JBiolChem 276(12):9437\u20139445","journal-title":"JBiolChem"},{"key":"5509_CR46","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/S0009-9120(03)00078-X","volume":"36","author":"S Rashid","year":"2003","unstructured":"Rashid S, Watanabe T, Sakaue T, Lewis GF (2003) Mechanisms of HDL lowering in insulin resistant, hypertriglyceridemic states: The combined effect of HDL triglyceride enrichment and elevated hepatic lipase activity. Clin Biochem 36:421\u2013429. https:\/\/doi.org\/10.1016\/S0009-9120(03)00078-X","journal-title":"Clin Biochem"},{"issue":"13","key":"5509_CR47","doi-asserted-by":"publisher","first-page":"12448","DOI":"10.1074\/jbc.M311718200","volume":"279","author":"ST Thuahnai","year":"2004","unstructured":"Thuahnai ST, Lund-Katz S, Dhanasekaran P et al (2004) Scavenger receptor class B type I-mediated cholesteryl ester-selective uptake and efflux of unesterified cholesterol: Influence of high density lipoprotein size and structure. J Biol Chem 279(13):12448\u201312455. https:\/\/doi.org\/10.1074\/jbc.M311718200","journal-title":"J Biol Chem"},{"issue":"45","key":"5509_CR48","doi-asserted-by":"publisher","first-page":"26910","DOI":"10.1074\/jbc.270.45.26910","volume":"270","author":"DL Sparks","year":"1995","unstructured":"Sparks DL, Davidson WS, Lund-Katz S, Phillips MC (1995) Effects of the neutral lipid content of high density lipoprotein on apolipoprotein A-I structure and particle stability. J Biol Chem 270(45):26910\u201326917. https:\/\/doi.org\/10.1074\/jbc.270.45.26910","journal-title":"J Biol Chem"},{"key":"5509_CR49","doi-asserted-by":"publisher","first-page":"9279","DOI":"10.3892\/mmr.2017.7831","volume":"16","author":"P Zhang","year":"2017","unstructured":"Zhang P, Gao J, Pu C, Zhang Y (2017) Apolipoprotein status in type 2 diabetes mellitus and its complications (Review). Mol Med Rep 16:9279\u20139286. https:\/\/doi.org\/10.3892\/mmr.2017.7831","journal-title":"Mol Med Rep"},{"issue":"4","key":"5509_CR50","doi-asserted-by":"publisher","first-page":"520","DOI":"10.3390\/biom10040520","volume":"10","author":"KG Kheniser","year":"2020","unstructured":"Kheniser KG, Osme A, Kim C, Ilchenko S, Kasumov T, Kashyap SR (2020) Temporal Dynamics of High-Density Lipoprotein Proteome in Diet-Controlled Subjects with Type 2 Diabetes. Biomolecules 10(4):520. https:\/\/doi.org\/10.3390\/biom10040520","journal-title":"Biomolecules"},{"issue":"6","key":"5509_CR51","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/j.numecd.2013.12.011","volume":"24","author":"C Morgantini","year":"2014","unstructured":"Morgantini C, Meriwether D, Baldi S et al (2014) HDL lipid composition is profoundly altered in patients with type 2 diabetes and atherosclerotic vascular disease. Nutr Metab Cardiovasc Dis 24(6):594\u2013599. https:\/\/doi.org\/10.1016\/j.numecd.2013.12.011","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"9","key":"5509_CR52","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1111\/j.1464-5491.2008.02546.x","volume":"25","author":"M Mastorikou","year":"2008","unstructured":"Mastorikou M, Mackness B, Liu Y, Mackness M (2008) Glycation of paraoxonase-1 inhibits its activity and impairs the ability of high-density lipoprotein to metabolize membrane lipid hydroperoxides. Diabet Med 25(9):1049\u20131055. https:\/\/doi.org\/10.1111\/j.1464-5491.2008.02546.x","journal-title":"Diabet Med"},{"key":"5509_CR53","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1002\/biof.1549","volume":"46","author":"J Kotur-Stevuljevi\u0107","year":"2020","unstructured":"Kotur-Stevuljevi\u0107 J, Veki\u0107 J, Stefanovi\u0107 A et al (2020) Paraoxonase 1 and atherosclerosis-related diseases. BioFactors 46:193\u2013205. https:\/\/doi.org\/10.1002\/biof.1549","journal-title":"BioFactors"},{"issue":"6","key":"5509_CR54","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1007\/s00125-006-0244-1","volume":"49","author":"L Pers\u00e9gol","year":"2006","unstructured":"Pers\u00e9gol L, Verg\u00e8s B, Foissac M, Gambert P, Duvillard L (2006) Inability of HDL from type 2 diabetic patients to counteract the inhibitory effect of oxidised LDL on endothelium-dependent vasorelaxation. Diabetologia 49(6):1380\u20131386. https:\/\/doi.org\/10.1007\/s00125-006-0244-1","journal-title":"Diabetologia"},{"issue":"3","key":"5509_CR55","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/j.jacl.2017.03.013","volume":"11","author":"RFH Lemmers","year":"2017","unstructured":"Lemmers RFH, van Hoek M, Lieverse AG, Verhoeven AJM, Sijbrands EJG, Mulder MT (2017) The anti-inflammatory function of high-density lipoprotein in type II diabetes: A systematic review. J Clin Lipidol 11(3):712\u2013724.e5. https:\/\/doi.org\/10.1016\/j.jacl.2017.03.013","journal-title":"J Clin Lipidol"},{"key":"5509_CR56","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s11010-017-3165-z","volume":"440","author":"RAK Srivastava","year":"2018","unstructured":"Srivastava RAK (2018) Dysfunctional HDL in diabetes mellitus and its role in the pathogenesis of cardiovascular disease. Mol Cell Biochem 440:167\u2013187. https:\/\/doi.org\/10.1007\/s11010-017-3165-z","journal-title":"Mol Cell Biochem"},{"key":"5509_CR57","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.atherosclerosis.2017.07.015","volume":"265","author":"M Estruch","year":"2017","unstructured":"Estruch M, Mi\u00f1ambres I, Sanchez-Quesada JL et al (2017) Increased inflammatory effect of electronegative LDL and decreased protection by HDL in type 2 diabetic patients. Atherosclerosis 265:292\u2013298. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2017.07.015","journal-title":"Atherosclerosis"},{"issue":"7","key":"5509_CR58","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1194\/jlr.M004085","volume":"51","author":"B Shao","year":"2010","unstructured":"Shao B, Tang C, Heinecke JW, Oram JF (2010) Oxidation of apolipoprotein A-I by myeloperoxidase impairs the initial interactions with ABCA1 required for signaling and cholesterol export. J Lipid Res 51(7):1849\u20131858. https:\/\/doi.org\/10.1194\/jlr.M004085","journal-title":"J Lipid Res"},{"issue":"11","key":"5509_CR59","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.5551\/jat.39156","volume":"24","author":"M Tsujita","year":"2017","unstructured":"Tsujita M, Hossain MA, Lu R, Tsuboi T, Okumura-Noji K, Yokoyama S (2017) Exposure to high glucose concentration decreases cell surface abca1 and hdl biogenesis in hepatocytes. J Atheroscler Thromb 24(11):1132\u20131149. https:\/\/doi.org\/10.5551\/jat.39156","journal-title":"J Atheroscler Thromb"},{"issue":"4","key":"5509_CR60","first-page":"237","volume":"8","author":"BG Drew","year":"2012","unstructured":"Drew BG, Rye KA, Duffy SJ, Barter P, Kingwell BA (2012) The emerging role of HDL in glucose metabolism. NatRevEndocrinol 8(4):237\u2013245","journal-title":"NatRevEndocrinol"},{"issue":"11","key":"5509_CR61","doi-asserted-by":"publisher","first-page":"2915","DOI":"10.2337\/db17-0199","volume":"66","author":"J Liu","year":"2017","unstructured":"Liu J, van Klinken JB, Semiz S et al (2017) A Mendelian Randomization Study of Metabolite Profiles, Fasting Glucose, and Type 2 Diabetes. Diabetes 66(11):2915\u20132926. https:\/\/doi.org\/10.2337\/db17-0199","journal-title":"Diabetes"},{"issue":"1","key":"5509_CR62","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1097\/MOL.0000000000000253","volume":"27","author":"K-A Rye","year":"2016","unstructured":"Rye K-A, Barter PJ, Cochran BJ (2016) Apolipoprotein A-I interactions with insulin secretion and production. Curr Opin Lipidol 27(1):8\u201313. https:\/\/doi.org\/10.1097\/MOL.0000000000000253","journal-title":"Curr Opin Lipidol"},{"issue":"21","key":"5509_CR63","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1161\/CIRCULATIONAHA.109.870709","volume":"120","author":"AC Calkin","year":"2009","unstructured":"Calkin AC, Drew BG, Ono A et al (2009) Reconstituted high-density lipoprotein attenuates platelet function in individuals with type 2 diabetes mellitus by promoting cholesterol efflux. Circulation 120(21):2095\u20132104. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.109.870709","journal-title":"Circulation"},{"key":"5509_CR64","doi-asserted-by":"crossref","unstructured":"Kruit JK, Brunham LR, Verchere CB, Hayden MR (2010) HDL and LDL cholesterol significantly influence beta-cell function in type 2 diabetes mellitus. Curr Opin Lipidol 21(3):178\u2013185","DOI":"10.1097\/MOL.0b013e328339387b"},{"issue":"6","key":"5509_CR65","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1007\/s00125-010-1691-2","volume":"53","author":"JK Kruit","year":"2010","unstructured":"Kruit JK, Kremer PHC, Dai L et al (2010) Cholesterol efflux via ATP-binding cassette transporter A1 (ABCA1) and cholesterol uptake via the LDL receptor influences cholesterol-induced impairment of beta cell function in mice. Diabetologia 53(6):1110\u20131119. https:\/\/doi.org\/10.1007\/s00125-010-1691-2","journal-title":"Diabetologia"},{"issue":"8","key":"5509_CR66","first-page":"1642","volume":"30","author":"MA Fryirs","year":"2010","unstructured":"Fryirs MA, Barter PJ, Appavoo M et al (2010) Effects of high-density lipoproteins on pancreatic beta-cell insulin secretion. Arter 30(8):1642\u20131648","journal-title":"Arter"},{"issue":"3","key":"5509_CR67","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1093\/cvr\/cvu143","volume":"103","author":"EA Von","year":"2014","unstructured":"Von EA, Widmann C (2014) High-density lipoprotein, beta cells, and diabetes. Cardiovasc 103(3):384\u2013394","journal-title":"Cardiovasc"},{"issue":"7","key":"5509_CR68","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.2337\/db15-1493","volume":"65","author":"J Domingo-Esp\u00edn","year":"2016","unstructured":"Domingo-Esp\u00edn J, Lindahl M, Nilsson-Wolanin O, Cushman SW, Stenkula KG, Lagerstedt JO (2016) Dual actions of apolipoprotein A-I on glucose-stimulated insulin secretion and insulin-independent peripheral tissue glucose uptake lead to increased heart and skeletal muscle glucose disposal. Diabetes 65(7):1838\u20131848. https:\/\/doi.org\/10.2337\/db15-1493","journal-title":"Diabetes"},{"issue":"OCT","key":"5509_CR69","doi-asserted-by":"publisher","first-page":"645","DOI":"10.3389\/fendo.2018.00645","volume":"9","author":"K Matsumura","year":"2018","unstructured":"Matsumura K, Tamasawa N, Daimon M (2018) Possible insulinotropic action of apolipoprotein A-I through the ABCA1\/Cdc42\/cAMP\/PKA pathway in MIN6 cells. Front Endocrinol (Lausanne) 9(OCT):645. https:\/\/doi.org\/10.3389\/fendo.2018.00645","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"24","key":"5509_CR70","doi-asserted-by":"publisher","first-page":"9641","DOI":"10.1073\/pnas.1201433109","volume":"109","author":"F Wang","year":"2012","unstructured":"Wang F, Kohan AB, Kindel TL et al (2012) Apolipoprotein A-IV improves glucose homeostasis by enhancing insulin secretion. Proc Natl Acad Sci U S A 109(24):9641\u20139646. https:\/\/doi.org\/10.1073\/pnas.1201433109","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"5509_CR71","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1194\/jlr.M032904","volume":"54","author":"J Dalla-Riva","year":"2013","unstructured":"Dalla-Riva J, Stenkula KG, Petrlova J, Lagerstedt JO (2013) Discoidal HDL and apoA-I-derived peptides improve glucose uptake in skeletal muscle. J Lipid Res 54(5):1275\u20131282","journal-title":"J Lipid Res"},{"issue":"9","key":"5509_CR72","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1016\/j.cellsig.2015.05.003","volume":"27","author":"P Song","year":"2015","unstructured":"Song P, Kwon Y, Yea K et al (2015) Apolipoprotein a1 increases mitochondrial biogenesis through AMP-activated protein kinase. Cell Signal 27(9):1873\u20131881. https:\/\/doi.org\/10.1016\/j.cellsig.2015.05.003","journal-title":"Cell Signal"},{"issue":"4","key":"5509_CR73","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1007\/s00125-014-3162-7","volume":"57","author":"KG Stenkula","year":"2014","unstructured":"Stenkula KG, Lindahl M, Petrlova J et al (2014) Single injections of apoA-I acutely improve in vivo glucose tolerance in insulin-resistant mice. Diabetol 57(4):797\u2013800. https:\/\/doi.org\/10.1007\/s00125-014-3162-7","journal-title":"Diabetol"},{"issue":"1","key":"5509_CR74","doi-asserted-by":"publisher","first-page":"e013531","DOI":"10.1161\/JAHA.119.013531","volume":"9","author":"B Manandhar","year":"2020","unstructured":"Manandhar B, Cochran BJ, Rye KA (2020) Role of High-Density Lipoproteins in Cholesterol Homeostasis and Glycemic Control. J Am Heart Assoc 9(1):e013531. https:\/\/doi.org\/10.1161\/JAHA.119.013531","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"5509_CR75","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1038\/s41598-018-38014-3","volume":"9","author":"S Tang","year":"2019","unstructured":"Tang S, Tabet F, Cochran BJ et al (2019) Apolipoprotein A-I enhances insulin-dependent and insulin-independent glucose uptake by skeletal muscle. Sci Rep 9(1):1350. https:\/\/doi.org\/10.1038\/s41598-018-38014-3","journal-title":"Sci Rep"},{"key":"5509_CR76","doi-asserted-by":"publisher","first-page":"100949","DOI":"10.1016\/j.molmet.2020.01.013","volume":"35","author":"AM Fritzen","year":"2020","unstructured":"Fritzen AM, Domingo-Esp\u00edn J, Lundsgaard AM et al (2020) ApoA-1 improves glucose tolerance by increasing glucose uptake into heart and skeletal muscle independently of AMPK\u03b12. Mol Metab 35:100949. https:\/\/doi.org\/10.1016\/j.molmet.2020.01.013","journal-title":"Mol Metab"},{"issue":"3","key":"5509_CR77","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.jdiacomp.2018.10.015","volume":"33","author":"D de Luis","year":"2019","unstructured":"de Luis D, Izaola O, Primo D, Aller R (2019) Role of rs670 variant of APOA1 gene on metabolic response after a high fat vs. a low fat hypocaloric diets in obese human subjects. J Diabetes Complicat 33(3):249\u2013254. https:\/\/doi.org\/10.1016\/j.jdiacomp.2018.10.015","journal-title":"J Diabetes Complicat"},{"issue":"7","key":"5509_CR78","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1007\/s00125-019-4877-2","volume":"62","author":"SJ Edmunds","year":"2019","unstructured":"Edmunds SJ, Li\u00e9bana-Garc\u00eda R, Nilsson O et al (2019) ApoAI-derived peptide increases glucose tolerance and prevents formation of atherosclerosis in mice. Diabetologia 62(7):1257\u20131267. https:\/\/doi.org\/10.1007\/s00125-019-4877-2","journal-title":"Diabetologia"},{"issue":"8","key":"5509_CR79","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1007\/s40618-020-01187-8","volume":"43","author":"A Ochoa-Guzm\u00e1n","year":"2020","unstructured":"Ochoa-Guzm\u00e1n A, Moreno-Mac\u00edas H, Guill\u00e9n-Quintero D et al (2020) R230C but not \u2212 565C\/T variant of the ABCA1 gene is associated with type 2 diabetes in Mexicans through an effect on lowering HDL-cholesterol levels. J Endocrinol Investig 43(8):1061\u20131071. https:\/\/doi.org\/10.1007\/s40618-020-01187-8","journal-title":"J Endocrinol Investig"},{"issue":"6","key":"5509_CR80","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.arcmed.2015.07.008","volume":"46","author":"MA Gamboa-Mel\u00e9ndez","year":"2015","unstructured":"Gamboa-Mel\u00e9ndez MA, Galindo-G\u00f3mez C, Ju\u00e1rez-Mart\u00ednez L et al (2015) Novel Association of the R230C Variant of the ABCA1 Gene with High Triglyceride Levels and Low High-density Lipoprotein Cholesterol Levels in Mexican School-age Children with High Prevalence of Obesity. Arch Med Res 46(6):495\u2013501. https:\/\/doi.org\/10.1016\/j.arcmed.2015.07.008","journal-title":"Arch Med Res"},{"issue":"12","key":"5509_CR81","doi-asserted-by":"publisher","first-page":"4076","DOI":"10.2337\/db14-0548","volume":"63","author":"HW de","year":"2014","unstructured":"de HW, Karasinska JM, Ruddle P, Hayden MR (2014) Hepatic ABCA1 expression improves beta-cell function and glucose tolerance. Diabetes 63(12):4076\u20134082","journal-title":"Diabetes"},{"key":"5509_CR82","doi-asserted-by":"crossref","unstructured":"Brunham LR, Kruit JK, Pape TD et al (2007) Beta-cell ABCA1 influences insulin secretion, glucose homeostasis and response to thiazolidinedione treatment. Nat Med 13(3):340\u2013347","DOI":"10.1038\/nm1546"},{"issue":"12","key":"5509_CR83","doi-asserted-by":"publisher","first-page":"3186","DOI":"10.2337\/db11-0081","volume":"60","author":"JK Kruit","year":"2011","unstructured":"Kruit JK, Wijesekara N, Fox JE et al (2011) Islet cholesterol accumulation due to loss of ABCA1 leads to impaired exocytosis of insulin granules. Diabetes 60(12):3186\u20133196. https:\/\/doi.org\/10.2337\/db11-0081","journal-title":"Diabetes"},{"issue":"3","key":"5509_CR84","doi-asserted-by":"publisher","first-page":"659","DOI":"10.2337\/db11-1341","volume":"61","author":"JK Kruit","year":"2012","unstructured":"Kruit JK, Wijesekara N, Westwell-Roper C et al (2012) Loss of both ABCA1 and ABCG1 results in increased disturbances in islet sterol homeostasis, inflammation, and impaired beta-cell function. Diabetes 61(3):659\u2013664. https:\/\/doi.org\/10.2337\/db11-1341","journal-title":"Diabetes"},{"issue":"3","key":"5509_CR85","doi-asserted-by":"publisher","first-page":"653","DOI":"10.2337\/db11-0944","volume":"61","author":"N Wijesekara","year":"2012","unstructured":"Wijesekara N, Zhang LH, Kang MH et al (2012) miR-33a modulates ABCA1 expression, cholesterol accumulation, and insulin secretion in pancreatic islets. Diabetes 61(3):653\u2013658. https:\/\/doi.org\/10.2337\/db11-0944","journal-title":"Diabetes"},{"issue":"1","key":"5509_CR86","doi-asserted-by":"publisher","first-page":"193","DOI":"10.2337\/db14-0436","volume":"64","author":"MR Rickels","year":"2015","unstructured":"Rickels MR, Goeser ES, Fuller C et al (2015) Loss-of-function mutations in ABCA1 and enhanced \u03b2-cell secretory capacity in young adults. Diabetes 64(1):193\u2013199. https:\/\/doi.org\/10.2337\/db14-0436","journal-title":"Diabetes"},{"issue":"6","key":"5509_CR87","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1016\/j.bbadis.2019.02.003","volume":"1865","author":"E Xepapadaki","year":"2019","unstructured":"Xepapadaki E, Maulucci G, Constantinou C et al (2019) Impact of apolipoprotein A1- or lecithin:cholesterol acyltransferase-deficiency on white adipose tissue metabolic activity and glucose homeostasis in mice. Biochim Biophys Acta - Mol Basis Dis 1865(6):1351\u20131360. https:\/\/doi.org\/10.1016\/j.bbadis.2019.02.003","journal-title":"Biochim Biophys Acta - Mol Basis Dis"},{"issue":"1","key":"5509_CR88","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1161\/01.RES.69.1.216","volume":"69","author":"MM Gleason","year":"1991","unstructured":"Gleason MM, Medow MS, Tulenko TN (1991) Excess membrane cholesterol alters calcium movements, cytosolic calcium levels, and membrane fluidity in arterial smooth muscle cells. Circ Res 69(1):216\u2013227. https:\/\/doi.org\/10.1161\/01.RES.69.1.216","journal-title":"Circ Res"}],"container-title":["Diabetologia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-021-05509-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00125-021-05509-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-021-05509-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,13]],"date-time":"2022-07-13T00:02:35Z","timestamp":1657670555000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00125-021-05509-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,13]]},"references-count":88,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["5509"],"URL":"https:\/\/doi.org\/10.1007\/s00125-021-05509-0","relation":{},"ISSN":["0012-186X","1432-0428"],"issn-type":[{"value":"0012-186X","type":"print"},{"value":"1432-0428","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,13]]},"assertion":[{"value":"1 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}